These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28178849)

  • 21. Adaptive Design: A Review of the Technical, Statistical, and Regulatory Aspects of Implementation in a Clinical Trial.
    Cerqueira FP; Jesus AMC; Cotrim MD
    Ther Innov Regul Sci; 2020 Jan; 54(1):246-258. PubMed ID: 32008232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A seamless phase II/III design with sample-size re-estimation.
    Bischoff W; Miller F
    J Biopharm Stat; 2009 Jul; 19(4):595-609. PubMed ID: 20183428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adaptive designs for pivotal trials: discussion points from the PSI Adaptive Design Expert Group.
    Phillips AJ; Keene ON;
    Pharm Stat; 2006; 5(1):61-6. PubMed ID: 17080929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Point estimation and p-values in phase II adaptive two-stage designs with a binary endpoint.
    Kunzmann K; Kieser M
    Stat Med; 2017 Mar; 36(6):971-984. PubMed ID: 28028823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial: an adaptive trial design case study.
    Connor JT; Broglio KR; Durkalski V; Meurer WJ; Johnston KC
    Trials; 2015 Mar; 16():72. PubMed ID: 25885963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A free gift: an adaptive strategy in a single-arm trial using an exact test through the binomial distribution.
    Wang J
    J Biopharm Stat; 2012; 22(6):1127-36. PubMed ID: 23075012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Group sequential, sample size re-estimation and two-stage adaptive designs in clinical trials: a comparison.
    Shih WJ
    Stat Med; 2006 Mar; 25(6):933-41. PubMed ID: 16220505
    [No Abstract]   [Full Text] [Related]  

  • 28. Adaptive seamless designs with interim treatment selection: a case study in oncology.
    Carreras M; Gutjahr G; Brannath W
    Stat Med; 2015 Apr; 34(8):1317-33. PubMed ID: 25640198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adaptive clinical trials: progress and challenges.
    Coffey CS; Kairalla JA
    Drugs R D; 2008; 9(4):229-42. PubMed ID: 18588354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An optimised multi-arm multi-stage clinical trial design for unknown variance.
    Grayling MJ; Wason JMS; Mander AP
    Contemp Clin Trials; 2018 Apr; 67():116-120. PubMed ID: 29474933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design considerations for Factorial Adaptive Multi-Arm Multi-Stage (FAST) clinical trials.
    Beall J; Elm J; Semler MW; Wang L; Rice T; Kamel H; Mack W; Mistry AM
    Trials; 2024 Sep; 25(1):608. PubMed ID: 39261887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statistical analysis for two-stage seamless design with different study endpoints.
    Chow SC; Lu Q; Tse SK
    J Biopharm Stat; 2007; 17(6):1163-76. PubMed ID: 18027223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal flexible sample size design with robust power.
    Zhang L; Cui L; Yang B
    Stat Med; 2016 Aug; 35(19):3385-96. PubMed ID: 26999385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design of randomized controlled trials.
    Stanley K
    Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
    [No Abstract]   [Full Text] [Related]  

  • 37. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
    Shan G; Ma C; Hutson AD; Wilding GE
    J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two-stage seamless transition design from open-label single-arm to randomized double-arm clinical trials.
    Shi H; Yin G
    Stat Methods Med Res; 2018 Jan; 27(1):158-171. PubMed ID: 28034171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bayesian design and analysis of composite endpoints in clinical trials with multiple dependent binary outcomes.
    Zaslavsky BG
    Pharm Stat; 2013; 12(4):207-12. PubMed ID: 23625660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations.
    Schmidli H; Bretz F; Racine A; Maurer W
    Biom J; 2006 Aug; 48(4):635-43. PubMed ID: 16972715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.